Katherine A. Hoadley. The existing regulations under the Human Medicines Regulations 2012 for the disapplication of certain advertising restrictions for unlicensed vaccines are expanded by these regulations to permit temporary authorisation of any medicinal products for the purposes of any campaign approved by ministers. Temporary authorisation of vaccine BNT162b2. On 2 December 2020, a temporary authorisation was issued under Regulation 174 of the Human Medicines Regulations 2012 (as amended by Regulation 174A) for the implementation of the first COVID-19 vaccine, the Pfizer/BioNTech (BNT162b2), to be used in the United Kingdom. The authorisation was subject to a number of conditions which fall under 	Human Medicines (Coronavirus and Influenza) (Amendment) Regulations 2020
10986733	Regulation 174A(1) of these amending regulations. The temporary authorisation meant that a new COVID-19 vaccine could be approved by the MHRA without having to wait for the usual approval of the European Medicines Agency. Human Medicines (Coronavirus and Influenza) (Amendment) Regulations 2020 The Human Medicines (Coronavirus and Influenza) (Amendment) Regulations 2020 (SI 2020/1125) is a statutory instrument (SI) that was laid before parliament on 16 October 2020 to make provision for the strengthening of existing regulations that allow for the temporary authorisation of the supply of unlicensed medicines, including vaccines, in response to certain public health threats, and for the 	Human Medicines (Coronavirus and Influenza) (Amendment) Regulations 2020
10986734	Katherine A. Hoadley Katherine A. Hoadley Katherine A. Hoadley is an American breast cancer researcher. , she has served as the Associate Director of Cancer Genomics for the High-Throughput Sequencing Facility at UNC Lineberger Comprehensive Cancer Center. Her research is focused on understanding the biology of cancer through gene expression analyses and integrative genomic approaches. Early life and education. Hoadley was born and raised in Shepherdstown, West Virginia to a toxicologist father. Her first job was at the United States Department of Agriculture at the age of 16 doing plant research. Hoadley earned her Bachelor of Arts and Bachelor of Science degree from 	Katherine A. Hoadley
10986735	the West Virginia Wesleyan College where she also competed in track and field. She later earned her PhD from the University of North Carolina at Chapel Hill (UNC). Career. Upon completing her PhD, Hoadley continued to study the complexity of breast cancer as a Research Assistant Professor at UNC. While serving in this role, she worked alongside D. Neil Hayes to document four molecular subtypes of squamous cell cancer for the first time. In 2011, she was the inaugural co-recipient of the new Weatherspoon Family Brain Tumor Research Award for her contributions to the analysis of glioblastomas. The following 	Katherine A. Hoadley
10986736	year, Hoadley co-led a clinical trial testing a combination therapy for basal-like breast cancer which found that a combination of two drugs with promising preclinical results was not as effective as previously believed. A few years later, Hoadley was a lead researcher at The Cancer Genome Atlas (TCGA) which analyzed over 3,500 tumors across 12 different tissue types to see how they compared to one another. The results of the study found that one in ten cancers analyzed would be classified differently using their new approach. In 2015, she helped identify a group of women with HER2 positive 	Katherine A. Hoadley
10986737	breast cancer who could benefit from less intensive targeted treatment using molecular profiling of patients’ breast cancer tumors. Upon publishing the results, researchers said the findings could spare unnecessary treatment for those patients and help save health care dollars". Hoadley also found that 51 percent of patients had high expression levels of genes predominately expressed by immune cell subsets. In 2016, Hoadley co-identified a particular gene expression pattern in normal-appearing breast tissue around tumors that was linked to lower survival rates for women with estrogen receptor-positive breast cancer. As a result of her research, she received a  grant from the Susan G. Komen for the Cure organization "to study the genetic and immune cell features of basal-like breast cancer, a poorly understood subtype of breast cancer." The following year, Hoadley was appointed Associate Director of Cancer Genomics for the High-Throughput Sequencing Facility and eventually named an assistant professor in UNC's Department of Genetics. During the COVID-19 pandemic in North America, Hoadley was the recipient of the Marion R. Wright Award for Scientific Excellence as "an exemplary researcher within the field of metastatic breast cancer within their first three years on faculty." Her work was  also listed among the most influential scientific papers on Clarivate’s 2020 Highly Cited Researchers list. Katherine A. Hoadley Katherine A. Hoadley is an American breast cancer researcher. , she has served as the Associate Director of Cancer Genomics for the High-Throughput Sequencing Facility at UNC Lineberger Comprehensive Cancer Center. Her research is focused on understanding the biology of cancer through gene expression analyses and integrative genomic approaches. Early life and education. Hoadley was born and raised in Shepherdstown, West Virginia to a toxicologist father. Her first job was at the United States Department of Agriculture at the age of